Anthea Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anthea Cheng has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Claire E. Styles
Australian Red Cross Lifeblood Melbourne Victoria Australia
3 shared publications - Veronica C. Hoad
Australian Red Cross Lifeblood Melbourne Victoria Australia
3 shared publications - Anindita Das
Pathology and Clinical Governance Australian Red Cross Lifeblood Melbourne Victoria Australia
2 shared publications Aoife Raftery
2 shared publicationsChristof Jungbauer
2 shared publicationsDaniele Prati
2 shared publications
Latest Publications
- 2 September 2026
- Published by Wiley in Vox Sanguinis
Evaluating Australia's plasma pathway and rethinking transgender donor sexual activity restrictions: Zero donor detections of transfusion‐transmissible infections in 6 months following changes to source plasma donation eligibility for sexual activity and HIV pre‐exposure prophylaxis
Background and Objectives: Sexual activity–based blood donation restrictions aim to reduce incident transfusion‐transmissible infections (TTIs) but are not required for source plasma because of additional pathogen reduction. On 13 July 2025, Australian Red Cross Lifeblood introduced a plasma pathway (PP) allowing previously ineligible individuals to donate source plasma irrespective of recent sexual activity or human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) use. This study describes donor demographics and donation prevalence of tested TTIs from the program's first 6 months. Separately, associated PP changes facilitated a contemporary TTI prevalence estimate among transgender donors during this period. Materials and Methods: Descriptive demographics and TTI results were extracted from identified cohort donors from 13 July 2025 to 13 January 2026. TTI prevalence (per 10,000 plasma donations) was estimated by detected TTIs divided by the total number of donations. Results: The PP supported 6673 donations from 7832 attendances by 3465 donors over 6 months. Zero (upper 95% confidence limit 6.94 per 10,000 donations) cases of HIV, hepatitis B virus or hepatitis C virus were detected. New donors constituted 40% of PP donors. Donations were predominantly from men reporting sex with men without (48%) or with PrEP use (30%). No TTIs (0, upper 95% confidence limit 25.76 per 10,000 donations) were detected from transgender donors during this period. Conclusion: TTI prevalence was lower than predicted. The PP demonstrates an inclusive way to limit restrictions on sexual activity and PrEP use without changing the safety profile. Other blood services should consider its introduction.
- 2 September 2026
- Published by Wiley in Vox Sanguinis
Evaluating Australia's plasma pathway and rethinking transgender donor sexual activity restrictions: Zero donor detections of transfusion‐transmissible infections in 6 months following changes to source plasma donation eligibility for sexual activity and HIV pre‐exposure prophylaxis
Background and Objectives: Sexual activity–based blood donation restrictions aim to reduce incident transfusion‐transmissible infections (TTIs) but are not required for source plasma because of additional pathogen reduction. On 13 July 2025, Australian Red Cross Lifeblood introduced a plasma pathway (PP) allowing previously ineligible individuals to donate source plasma irrespective of recent sexual activity or human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) use. This study describes donor demographics and donation prevalence of tested TTIs from the program's first 6 months. Separately, associated PP changes facilitated a contemporary TTI prevalence estimate among transgender donors during this period. Materials and Methods: Descriptive demographics and TTI results were extracted from identified cohort donors from 13 July 2025 to 13 January 2026. TTI prevalence (per 10,000 plasma donations) was estimated by detected TTIs divided by the total number of donations. Results: The PP supported 6673 donations from 7832 attendances by 3465 donors over 6 months. Zero (upper 95% confidence limit 6.94 per 10,000 donations) cases of HIV, hepatitis B virus or hepatitis C virus were detected. New donors constituted 40% of PP donors. Donations were predominantly from men reporting sex with men without (48%) or with PrEP use (30%). No TTIs (0, upper 95% confidence limit 25.76 per 10,000 donations) were detected from transgender donors during this period. Conclusion: TTI prevalence was lower than predicted. The PP demonstrates an inclusive way to limit restrictions on sexual activity and PrEP use without changing the safety profile. Other blood services should consider its introduction.
- Open Access
- 8 June 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (8) , 846-857
Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion‐Transmitted Infectious Diseases Working Party, Bacteria Subgroup
Background and Objectives: High‐income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.Materials and Methods: Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion‐Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.Results: PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.Conclusions: PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin‐producing Staphylococcus aureus.
- 8 June 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (8) , 846-857
Open AccessPlatelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion‐Transmitted Infectious Diseases Working Party, Bacteria Subgroup
Background and Objectives: High‐income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.Materials and Methods: Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion‐Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.Results: PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.Conclusions: PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin‐producing Staphylococcus aureus.
- 14 November 2024
- Published by Wiley in Vox Sanguinis
- Vol. 120 (2) , 207-238
International Forum on Donor‐ and Recipient‐triggered Lookback for Traditional Transfusion‐transmitted Infections: Responses
- 14 November 2024
- Published by Wiley in Vox Sanguinis
- Vol. 120 (2) , 207-238
International Forum on Donor‐ and Recipient‐triggered Lookback for Traditional Transfusion‐transmitted Infections: Responses
- 14 November 2024
- Published by Wiley in Vox Sanguinis
- Vol. 120 (2) , 197-206
International Forum on Donor‐ and Recipient‐triggered Lookback for Traditional Transfusion‐transmitted Infections: Summary
- 14 November 2024
- Published by Wiley in Vox Sanguinis
- Vol. 120 (2) , 197-206
International Forum on Donor‐ and Recipient‐triggered Lookback for Traditional Transfusion‐transmitted Infections: Summary
- Open Access
- 14 August 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (8) , e0047624
Improved efficiency using sequential automated immunoassays for syphilis screening in blood donors
Using sequential immunoassays for the screening of blood donors is well described for viral serology testing but not for the screening of syphilis. In this study, we report the evaluation results and 2-year sequential testing data using two highly sensitive automated serology assays, the Alinity s Syphilis chemiluminescent immunoassay for screening, with all repeatedly reactive samples then tested on the Elecsys Syphilis electrochemiluminescence immunoassay. We screened 1,767,782 blood donor samples between 7 July 2021 and 6 July 2023 and found the Alinity false-positive rate to be low at 0.08% (1,456/1,767,782). The common false-positive rate between the two assays was also low (3.83%, 58/1,514). Concordantly reactive samples were further tested using a Treponema pallidum particle agglutination test, a rapid plasma reagin test, and a fluorescent treponemal antibody absorption test. There were 262/1,376 concordantly reactive Alinity and Elecsys blood donor samples with reactivity on one or more of the confirmatory tests. A total of 26/1,376 donors had a current syphilis infection, 152/1,376 reported a past history of syphilis and had been treated, and 84/1,376 did not report a past history of syphilis. We suggest that future studies could explore the use of sequential immunoassays to aid in the serodiagnosis for syphilis. IMPORTANCE: The serodiagnosis for syphilis usually follows two methodologies—a “traditional” algorithm using a non-treponemal test followed by confirmation using a treponemal test, or a “reverse” algorithm using a treponemal test followed by a non-treponemal test. There are limited reports in the literature of using a modified reverse algorithm (treponemal test followed by a second treponemal test), and to the best of knowledge, there are currently no published articles using two highly sensitive automated immunoassays to aid the serodiagnosis of syphilis. In addition, the Treponema pallidum particle agglutination (TPPA) assay is commonly used as a confirmatory test for the diagnosis of syphilis. With the withdrawal of the TPPA assay from Australia and presumably from the global market also, alternative testing algorithms are now required. This study provides proof of concept for using sequential immunoassays in the diagnosis of syphilis.
- 14 August 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (8) , e0047624
Open AccessImproved efficiency using sequential automated immunoassays for syphilis screening in blood donors
Using sequential immunoassays for the screening of blood donors is well described for viral serology testing but not for the screening of syphilis. In this study, we report the evaluation results and 2-year sequential testing data using two highly sensitive automated serology assays, the Alinity s Syphilis chemiluminescent immunoassay for screening, with all repeatedly reactive samples then tested on the Elecsys Syphilis electrochemiluminescence immunoassay. We screened 1,767,782 blood donor samples between 7 July 2021 and 6 July 2023 and found the Alinity false-positive rate to be low at 0.08% (1,456/1,767,782). The common false-positive rate between the two assays was also low (3.83%, 58/1,514). Concordantly reactive samples were further tested using a Treponema pallidum particle agglutination test, a rapid plasma reagin test, and a fluorescent treponemal antibody absorption test. There were 262/1,376 concordantly reactive Alinity and Elecsys blood donor samples with reactivity on one or more of the confirmatory tests. A total of 26/1,376 donors had a current syphilis infection, 152/1,376 reported a past history of syphilis and had been treated, and 84/1,376 did not report a past history of syphilis. We suggest that future studies could explore the use of sequential immunoassays to aid in the serodiagnosis for syphilis. IMPORTANCE: The serodiagnosis for syphilis usually follows two methodologies—a “traditional” algorithm using a non-treponemal test followed by confirmation using a treponemal test, or a “reverse” algorithm using a treponemal test followed by a non-treponemal test. There are limited reports in the literature of using a modified reverse algorithm (treponemal test followed by a second treponemal test), and to the best of knowledge, there are currently no published articles using two highly sensitive automated immunoassays to aid the serodiagnosis of syphilis. In addition, the Treponema pallidum particle agglutination (TPPA) assay is commonly used as a confirmatory test for the diagnosis of syphilis. With the withdrawal of the TPPA assay from Australia and presumably from the global market also, alternative testing algorithms are now required. This study provides proof of concept for using sequential immunoassays in the diagnosis of syphilis.
- Open Access
- 27 October 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (1) , e14180
Revised nucleic acid test window periods: Applications and limitations in organ donation practice
Background: Nucleic acid test window periods for HIV, HCV, and HBV facilitate estimation of the residual risk of unexpected disease transmission and assist clinicians in determining the timeframe in which a recently acquired infection is at risk of nondetection.Objectives: Firstly, to provide revised estimates of the NAT window periods based on a currently used triplex NAT assay. Secondly, to examine their validity in organ donation and transplantation practice.Method: Estimates were based on the Procleix Ultrio Elite Assay (Grifols Diagnostic Solutions Inc. California, USA). The manufacturer's X50 and X95 limits of detection (LOD) were utilised. Viral doubling times of 0.85, 0.45, and 2.56 days and conversion factors for IU per ml to copies per mL of 0.6, 3.4, and 5 were assumed for HIV, HCV, and HBV respectively. Window periods were derived from the X50 and X95 LODs, based on a range of potential inoculum volumes.Results: Calculated X50 window periods were 5.1 (4.5–5.8), 2.7 (2.4–2.9), and 16.6 (14.2–19.1) days for HIV, HCV, and HBV respectively.Calculated X50 window periods, based on whole body plasma volume, were 11.8 (10.3–13.3), 6.2 (5.6–6.8) and 36.7 (31.3–42.1) days respectively.Conclusion: X50 NAT window periods were significantly shorter for HBV and HCV and sit at the lower range of previously published estimates for HIV . Current modeling assumptions may not account for all unexpected transmission events and may no longer be suitable for application to organ donation and transplantation. image
- 27 October 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (1) , e14180
Open AccessRevised nucleic acid test window periods: Applications and limitations in organ donation practice
Background: Nucleic acid test window periods for HIV, HCV, and HBV facilitate estimation of the residual risk of unexpected disease transmission and assist clinicians in determining the timeframe in which a recently acquired infection is at risk of nondetection.Objectives: Firstly, to provide revised estimates of the NAT window periods based on a currently used triplex NAT assay. Secondly, to examine their validity in organ donation and transplantation practice.Method: Estimates were based on the Procleix Ultrio Elite Assay (Grifols Diagnostic Solutions Inc. California, USA). The manufacturer's X50 and X95 limits of detection (LOD) were utilised. Viral doubling times of 0.85, 0.45, and 2.56 days and conversion factors for IU per ml to copies per mL of 0.6, 3.4, and 5 were assumed for HIV, HCV, and HBV respectively. Window periods were derived from the X50 and X95 LODs, based on a range of potential inoculum volumes.Results: Calculated X50 window periods were 5.1 (4.5–5.8), 2.7 (2.4–2.9), and 16.6 (14.2–19.1) days for HIV, HCV, and HBV respectively.Calculated X50 window periods, based on whole body plasma volume, were 11.8 (10.3–13.3), 6.2 (5.6–6.8) and 36.7 (31.3–42.1) days respectively.Conclusion: X50 NAT window periods were significantly shorter for HBV and HCV and sit at the lower range of previously published estimates for HIV . Current modeling assumptions may not account for all unexpected transmission events and may no longer be suitable for application to organ donation and transplantation. image
- Open Access
- 19 September 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (9) , 2346
Safety Analysis of Extended Platelet Shelf-Life with Large-Volume Delayed Sampling on BACT/ALERT® VIRTUO® in Australia
Transfusion-transmitted bacterial infection (TTBI) is the leading cause of transfusion-transmitted infections. Platelet components are more likely to be associated with bacterial contamination due to their storage requirements. Australian Red Cross Lifeblood introduced the bacterial contamination screening (BCS) of all platelet components in 2008. The process was recently updated with the use of BACT/ALERT® VIRTUO®, a large-volume delayed sampling (LVDS) protocol and extending platelet shelf-life to seven days. This article describes the results from the routine BCS of platelet components in Australia. Use of VIRTUO has resulted in lower false-positive rates, reducing wastage and improving platelet inventory. Our findings show that the combination of LVDS and VIRTUO improves the safety of platelet transfusions through earlier time to detection, especially for pathogenic bacterial species. Pathogenic bacteria grew within 24 h of incubation with a clear delineation between pathogenic and non-pathogenic species. The data show this protocol is very safe, with no TTBI cases during this time. There were no TTBI reports in recipients of platelet components that subsequently had a positive culture with Cutibacterium species, probably due to the low pathogenic potential of these organisms and slow replication in aerobic platelet bags. We conclude there is no advantage in incubating culture bottles beyond five days.
- 19 September 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (9) , 2346
Open AccessSafety Analysis of Extended Platelet Shelf-Life with Large-Volume Delayed Sampling on BACT/ALERT® VIRTUO® in Australia
Transfusion-transmitted bacterial infection (TTBI) is the leading cause of transfusion-transmitted infections. Platelet components are more likely to be associated with bacterial contamination due to their storage requirements. Australian Red Cross Lifeblood introduced the bacterial contamination screening (BCS) of all platelet components in 2008. The process was recently updated with the use of BACT/ALERT® VIRTUO®, a large-volume delayed sampling (LVDS) protocol and extending platelet shelf-life to seven days. This article describes the results from the routine BCS of platelet components in Australia. Use of VIRTUO has resulted in lower false-positive rates, reducing wastage and improving platelet inventory. Our findings show that the combination of LVDS and VIRTUO improves the safety of platelet transfusions through earlier time to detection, especially for pathogenic bacterial species. Pathogenic bacteria grew within 24 h of incubation with a clear delineation between pathogenic and non-pathogenic species. The data show this protocol is very safe, with no TTBI cases during this time. There were no TTBI reports in recipients of platelet components that subsequently had a positive culture with Cutibacterium species, probably due to the low pathogenic potential of these organisms and slow replication in aerobic platelet bags. We conclude there is no advantage in incubating culture bottles beyond five days.